AACR Conference Coverage

Strategies Identified To Reverse Obesity’s Lingering, Pro-Cancer Effects

(UNC Lineberger) Apr 15, 2018 - In preliminary findings presented at the American Association for Cancer Research Annual Meeting 2018 in Chicago, researchers from the lab of UNC Lineberger's Stephen Hursting, PhD, reported on a number of studies examining possible ways to reverse obesity-linked biological changes.

read press release

To Starve Pancreatic Tumors, Researchers Seek To Block ‘Self-Eating,’ Other Fuel Sources

(UNC Lineberger) Apr 13, 2018 - UNC Lineberger researchers led by Channing Der, PhD, are reporting preclinical findings for a potential two-treatment strategy to block multiple mechanisms of cancer cell metabolism in pancreatic cancer at the American Association for Cancer Research Annual Meeting in Chicago. The findings will be presented from 8 a.m. to noon on Wednesday.

read press release

Global ROS1 Initiative Combines Patient Experience With Researcher Expertise To Target ROS1 Cancer Wherever It Grows

(UCCC/Colorado Cancer Blogs) Apr 17, 2018 - Cancer patients have often organized support and informational groups around their disease types. Now a presentation at the American Association for Cancer Research (AACR) Annual Meeting 2018 describes the first research-focused group of patients organized around the genetic mutation that creates their cancer, namely changes to the gene ROS1.

read article

Socioeconomic Factors, Not Race Or Ethnicity, Linked To Treatment Refusal For Advanced Lung Cancer

(Healio) Apr 17, 2018 - Socioeconomic factors influenced whether patients with stage IV non-small cell lung cancer refused cancer treatment, according to study results presented at American Association for Cancer Research Annual Meeting.

read article

Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at AACR in Chicago

(Spectrum) Apr 17, 2018 - Spectrum Pharmaceuticals announced a poster presentation of data from preclinical and clinical studies evaluating poziotinib in HER2 exon 20 mutations in non-small cell lung cancer (NSCLC) and summarizing a dataset of the prevalence of HER2 exon 20 across solid tumors by scientists from MD Anderson at AACR 2018.

read corporate press release

In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

(BMS) Apr 16, 2018 - Patients treated with Opdivo experienced a 32% reduction in the risk of death after two years minimum follow-up; Opdivo remains the only PD-1 inhibitor to demonstrate statistically significant OS versus standard chemotherapy in the primary analysis of a Phase 3 trial in these patients, with benefit maintained with long-term follow-up.

read corporate press release

How Does Leukemia Escape From Immunotherapy?

(Fred Hutch News Service) Apr 16, 2018 - A new study highlights one way that an aggressive leukemia can wriggle its way free of targeted attack by a high-tech strategy for immune-based therapy.

read article

Beyond PD-L1: Taking Away TIM3 And Tregs Stops Cancer Regrowth After Immunotherapy

(UCCC/Colorado Cancer Blogs) Apr 16, 2018 - Radiation treatment can boost the effectiveness of anti-cancer immunotherapy.

read article

When Prostate Cancer Reaches Bone, Bone Cells May Drive Overall Growth Of The Disease

(UCCC/Colorado Cancer Blogs) Apr 16, 2018 - When prostate cancer metastasizes to bone, it can become especially dangerous – not only with its action in the bone but, interestingly, with increased aggressiveness of the overall cancer itself.

read article

Experts Discuss Insights From Molecular Tumor Boards, Clinical NGS Programs at AACR

(GenomeWeb) Apr 17, 2018 – Molecular tumor boards are continuing to gain treatment clues from individuals' cancer sequences, at the same time as growing cancer data collections reveal broader tumor features across patients.

read article (free registration required)

Abramson Cancer Center Studies Show Promise of Immunotherapy Combinations, Including CAR T

(Penn Medicine) Apr 17, 2018 - As immunotherapies continue to make up a larger share of new cancer drugs, researchers are looking for the most effective ways to use these cutting edge treatments in combination with each or with other pre-existing options.

read press release

GRAIL Announces Data from Prototype Blood Tests for Early Cancer Detection

(MarketWatch) Apr 17, 2018 - GRAIL, Inc. today announced initial results from its Circulating Cell-Free Genome Atlas (CCGA) Study. Data from three prototype genome sequencing assays showed it may be feasible to develop a blood test for early detection of multiple cancer types with greater than 99 percent specificity.

read article

Roswell Park Researchers Identify Epigenetic Changes that May Help Explain Racial Disparities in Breast Cancer

(RPCI) Apr 18, 2018 - Roswell Park Comprehensive Cancer Center researchers have identified epigenetic differences in the breast cancer tumors of African-American women and women of European descent, shedding light on one mechanism by which race may influence the way breast cancer develops.

read press release

Three Solutions to Maximize the Clinical Benefit and Affordability of Targeted Cancer Drugs

(Penn LDI) Apr 18, 2018 - Spending on cancer drugs in the United States has nearly doubled in the past five years and continues to grow, imposing substantial financial burden on patients with cancer. One of the biggest drivers of this growth is targeted cancer drugs.

read article

Olaparib in Breast Cancer: PFS Is Significant but OS Is Not

(Medscape Medical News) Apr 18, 2018 - New results from the OlympiAD trial show that overall survival was not significant, but a breast cancer expert says that this will not affect uptake of olaparib for these patients.

read article (free registration required)

Will You Change How You Treat Lung Cancer?

(MedPage Today) Apr 17, 2018 - Results from a group of lung cancer trials presented at the annual meeting of the American Association for Cancer Research (AACR) could have practice-changing implications.

read article (free registration required)

Blood Test Shows Promise For Spotting Early Cancers

(Science Magazine) Apr 17, 2018 - The elusive dream is that a simple blood test could detect a small tumor growing in your body, giving doctors time to cure you before it’s too late. Today, scientists at GRAIL, a biotechnology company based in Menlo Park, California, that has drawn more than a billion dollars in investment, announced progress toward that goal here at the annual meeting of the American Association for Cancer Research.

read article

Cancer Wrap: Blueprint, Checkmate, More AACR News & Phase 3 Blues

(Xconomy National) Apr 18, 2018 - The big headlines from the American Association for Cancer Research meeting in Chicago were all about the battle over the latest lung cancer data, and for good reason. Lung cancer remains the deadliest cancer, but the Phase 3 data suggest that treatment options for some of the direst cases could soon rapidly expand.

read article

For Aggressive Breast Cancer In The Brain, Researchers Clarify Immune Response

(UNC Lineberger) Apr 17, 2018 - In a preliminary study presented at the American Association for Cancer Research Annual Meeting 2018 in Chicago, researchers led by UNC Lineberger's Benjamin Vincent, MD, and Carey Anders, MD, revealed findings for what kind of immune response the body is staging against triple negative breast cancer that has spread to the brain.

read press release

A Cancer Drug Tailored To Your Tumor? Experts Trade Barbs Over 'Precision Oncology'

(Science Magazine) Apr 24, 2018 - Last week, two prominent voices in the field faced off in a sometimes-tense debate on what’s often called precision oncology at the annual meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois. Their dispute threw a splash of cold water on a meeting packed with sessions on genome-based cancer treatments.

read article
Next Page